Recursion hopes to share results from a couple of phase 2 studies in the first half of 2025. One of those clinical trials is evaluating REC-4881 in treating familial adenomatous polyposis, a ...

SALT LAKE CITY, Nov. 20, 2024-- The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly ...

Recursion Pharmaceuticals formed in 2013, co-founded by Gibson. Three years later, the young company raised its Series A round of funding.